Tech Company M&A Transactions
Quellis Biosciences Acquisition
Quellis Biosciences, operating out of Boston, was purchased by Catabasis Pharmaceuticals. Deal value was $110 million.
Transaction Overview
Company Name
Acquired By
Announced On
2/1/2021
Transaction Type
M&A
Amount
$110,000,000
M&A Terms
The vision for the lead program, QLS-215, is to develop the best-in-class monoclonal antibody inhibitor of plasma kallikrein for HAE with infrequent dosing and sustained blood levels.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
240 Newbury St. 2nd Floor
Boston, MA 02116
USA
Boston, MA 02116
USA
Phone
Undisclosed
Website
Email Address
Overview
Quellis was founded to deliver best-in-class therapies to patients suffering serious rare diseases -- and underserved by current treatment options. The Company is based in Boston, and is led by partners from the biotech incubator Viridian LLC in collaboration with team at biotech accelerator Xontogeny LLC, and with funding from the Perceptive Xontogeny Venture Fund.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jonathan Violin
Chief Scientific Officer
Vahe Bedian
Browse more venture capital transactions:
Prev: 2/1/2021: Yotta Savings venture capital transaction
Next: 2/1/2021: Cutback Coach venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. All VC database entries on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs